NewAmsterdam Pharma Company N.V (NAMS)

Update: Executive Summary

NewAmsterdam Pharma continues to demonstrate impressive momentum, gaining 12.26% since the last report and reaching $41.30. Despite disappointing Q3 results with substantial revenue deviation from forecasts (-91.03%), the stock shows sustained growth driven by expectations of significant revenue expansion and ongoing investor interest in the biotechnology sector. The investment thesis remains intact, although operating losses and low current revenue require close attention to product portfolio development.

Key Updates

NewAmsterdam Pharma shares have risen 12.26% since the last report on October 29, reaching $41.30. Short-term dynamics demonstrate a sustained upward trend: +9.52% over 5 days and +15.25% over the month. Six-month growth totaled an impressive 138.59%, confirming strong investor interest in the company. The main event was the publication of Q3 results, showing substantial revenue deviation from expectations (-91.03%) and earnings per share loss with a deviation of -7.89%. Despite weak operational metrics, the market continues to positively assess the company's long-term prospects, reflected in the ongoing price rally.

Current Trend

NewAmsterdam Pharma is in a sustained upward trend with six-month growth of 138.59%. The current price of $41.30 represents a new local high, exceeding the previous level of $36.79. The short-term correction of -0.36% over the last day is insignificant in the context of monthly growth of +15.25%. Technical momentum remains positive, with shares consistently breaking through resistance levels. Key support levels are forming in the $36-37 range, where consolidation was previously observed. Volatility remains elevated, which is typical for biotechnology companies at the commercialization stage.

Investment Thesis

NewAmsterdam Pharma's investment thesis is based on expectations of significant revenue growth as the company transitions from the development stage to commercialization. According to forecasts, the company should demonstrate revenue growth of 59.1% annually, reflecting the potential of its product portfolio. Current valuation accounts for future cash flows from drug commercialization, despite ongoing operating losses growing at an average of 52% annually over the past five years. The market is willing to overlook current financial metrics in favor of long-term potential, which is characteristic of the biotechnology sector. The key risk remains the company's ability to meet revenue forecasts and achieve operational profitability.

Thesis Status

The investment thesis remains intact despite disappointing Q3 results. The revenue deviation of -91.03% from expectations indicates delays in commercialization, however market reaction remains positive with shares rising 12.26% following the earnings release. This suggests that investors are focused on long-term prospects of 59.1% annual revenue growth rather than current operational metrics. The increase in losses of 52% per year creates pressure on the cash position, but does not change the fundamental thesis about the product portfolio's potential. A critical factor for confirming the thesis will be the company's ability to demonstrate revenue acceleration in upcoming quarters and narrowing of operating losses.

Key Drivers

The main driver of current dynamics is sustained optimism regarding long-term revenue growth potential, despite weak quarterly results. Revenue growth forecast of 59.1% annually continues to support institutional investor interest. Q3 results with substantial revenue deviation (-91.03%) did not lead to sell-offs, indicating resilience of the investor base. Overall positive dynamics in the biotechnology sector also support the stock, as evidenced by activity in related sector companies. Technical momentum is reinforced by consistent breaking of highs and formation of new support levels.

Technical Analysis

NewAmsterdam Pharma shares demonstrate a strong upward trend with consistent breaking of local highs. The current price of $41.30 is near historical highs, while the short-term correction of -0.36% per day does not disrupt the overall picture. Key support levels have formed at $36.79 (previous high) and $35.72 (earlier resistance level that became support). Momentum indicators remain positive with growth of +9.52% over 5 days and +15.25% over the month. Six-month growth of 138.59% indicates sustained buyer interest. Trading volumes support the upward movement. The nearest resistance is at the psychological level of $42-43, a breakout of which could open the path to further growth. Correction risk exists in case of a decline below $36, which could lead to testing the $33 level.

Bullish Arguments

• Projected explosive revenue growth: The company expects revenue growth of 59.1% annually, reflecting significant commercial potential of the product portfolio and the possibility of transforming financial metrics. Source
• Sustained technical momentum: Six-month growth of 138.59% and monthly growth of 15.25% demonstrate strong investor interest and formation of a sustained upward trend with consistent breaking of highs. Source
• Market resilience to negative news: Despite Q3 revenue deviation of -91.03% from forecasts, shares rose 12.26%, indicating investor focus on long-term prospects rather than current results. Source
• Positive biotechnology sector dynamics: Overall interest in biotechnology companies supports the stock, creating a favorable backdrop for further sector growth. Source
• Formation of new support levels: Consistent elevation of price levels from $33 to $41.30 creates a technical base for continued growth with clear support levels at $36-37. Source

Bearish Arguments

• Critical revenue deviation from forecasts: Q3 revenue deviation of -91.03% from expectations indicates serious commercialization problems and raises doubts about the ability to meet growth forecasts of 59.1% annually. Source
• Accelerating operating losses: Company losses are growing at an average of 52% annually over the past five years, creating pressure on the cash position and may require additional financing with shareholder dilution. Source
• Earnings per share deviation from expectations: Q3 loss per share was 7.89% worse than forecasts, demonstrating inability to control operating expenses in conditions of low revenue. Source
• High valuation in absence of profitability: Share growth of 138.59% over six months amid ongoing losses creates correction risk in case of disappointment in commercialization pace or deterioration of sentiment in the biotechnology sector. Source
• Institutional activity in the sector: Exit of major institutional investors from positions in the biotechnology sector, as in the case of Bain Capital and Disc Medicine, may signal a reassessment of risks in the industry. Source